array(13) { ["code"]=> string(5) "en_gb" ["id"]=> string(2) "64" ["native_name"]=> string(6) "Global" ["major"]=> string(1) "0" ["active"]=> string(1) "1" ["default_locale"]=> string(5) "en_GB" ["encode_url"]=> string(1) "0" ["tag"]=> string(5) "en-gb" ["missing"]=> int(0) ["translated_name"]=> string(6) "Global" ["url"]=> string(35) "https://www.prosigna.com/resources/" ["country_flag_url"]=> string(90) "https://www.prosigna.com/wp-content/plugins/sitepress-multilingual-cms/res/flags/en_gb.png" ["language_code"]=> string(5) "en_gb" } native: Global
translated: Global
IN the US OUTSIDE the US
CONTACT US
You are now entering a page intended for healthcare professionals only, if you are a patient or a member of the public, we will address you to a dedicated webpage.

PROSIGNA PRODUCT INSERTS AND MSDS

Scientific Evidence Of The Prosigna Assay’s Clinical Performance

More comprehensive information for better treatment decisions

  • Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study


    READ MORE
  • Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens
    READ MORE
  • Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

    READ MORE
  • Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer





    READ MORE
  • Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
    READ MORE
  • The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer


    READ MORE
  • Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score
    READ MORE
  • PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor–Positive Early Breast Cancer


    READ MORE
  • Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer


    READ MORE
  • The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer
    READ MORE
  • Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype- Prosigna® Test in the management of early-stage breast cancers



    READ MORE
  • Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (NICE Diagnostic Guidance)





    READ MORE
  • Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
    READ MORE
  • Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study


    READ MORE

ONGOING CLINICAL STUDIES

PROSIGNA CENTERS

Select your country below to learn more about how you can have the Prosigna breast cancer assay performed on the locally available nCounter Analysis System.

  • Australia

    • Sonic Genetics

       

      Level 17, Grosvenor Place,
      225 George Street
      NSW 2000
      Sydney

      800-010-447 (Australia only)
      800-515-119

      www.sonicgenetics.com.au

       

  • Denmark

    • Prosigna is covered by all
      Health Care Regions in Denmark

  • France

    • Institut Claudius Regaud

       

      1, Avenue Irène Joliot-Curie
      Toulouse cedex 9 31059

      + 33 (0) 5 31 15 50 50 (Standard)
      33 (0) 5 31 15 52 01

      www.iuct-oncopole.fr

       

    • Institut Curie

       

      26, Rue d’Ulm
      Paris 75005

      + 33 (0) 1 56 24 55 00 (Standard)

      www.curie.fr

       

    • Centre Jean-Perrin

       

      58, rue Montalembert
      Clermont-Ferrand 63011

      + 33 (0) 4 73 27 80 80 (Standard)
      + 33 (0) 4 73 27 81 67

      www.cjp.fr

       

    • Centre Henri Becquerel

       

      1, Rue d’Amiens
      Rouen 76038

      + 33 (0) 2 32 08 29 75
      + 33 (0) 2 32 08 22 22

      www.becquerel.fr

       

    • Centre Oscar Lambret

       

      3, Rue Frédéric Combemale
      Lille 59000

      + 33 (0) 3 20 29 59 48

      www.centreoscarlambret.fr

       

    • Hospices Civils de Lyon

       

      165, Chemin du Grand Revoyet
      Pierre Benite 69495

      + 33 (0) 4 78 86 11 86

      www.chu-lyon.fr
      https://biobook.chu-lyon.fr/Home

       

    • Centre Léon Bérard

       

      Cheney B 2ème étage,
      28 rue Laennec
      Lyon Cedex 69373

      + 33 (0)4 78 78 28 28

      www.centreleonberard.fr

       

  • Germany
  • Hong Kong

    • DeNovo Service Limited

       

      18 / F, Block B, Vita Tower

      29 Wong Chuk Hang Road

      Wong Chuk Hang

      Hong Kong
      852-2523 1868

      852-2523-1021

      www.denovoservice.com

  • Italy

    • Anatomia Patologica ASST
      Sette-Laghi, Ospedale Macchi Varese

       

      Via O.Rossi 9
      Varese (VA) 21100

      (+39) 0332 270601

      www.asst-settelaghi.it

    • ASUR Marche – Ospedale Generale
      Di Macerata OU. 0f Anatomy – Pathology

       

      Via S. Lucia 2
      Macerata (MC) 62100

      (+39) 073 325 724 60

      http://www.asl9.marche.it/RepartiServizi.htm

    • CDI Centro Diagnostico Italiano S.p.A. Dipartimento di Genetica Molecolare e Citogenetica

       

      Via Egidio Folli
      50-20134 Milano

      (+39) 0248317056

      genetica@cdi.it
      www.cdi.it

    • IRCCS Fondazione Pascale Istituto Nazionale Tumori

       

      Via Mariano Semmola 53

      80131 Naples

      (+39)081 59031767

      www.istitutotumori.na.it

       

       

    • TOMALAB – Toma Advanced Biomedical Assays SpA

       

      Via Francesco Ferrer 25/27

      (+39) 345 7528732

      www.tomalab.it

    • U.O.C. Anatomia Patologica – Azienda Ospedaliera – Universitaria Senese

             

      Via delle Scotte
      6 53100 Siena   
      0577 233450 – 585850

      http://www.ao-siena.toscana.it/

    • Vanvitelli University Hospital

       

      Via Luciano Armanni 5
      Napoli (NA) 80138

      (+39) 081 5664004

      www.policliniconapoli.it

  • Israel

    • Hadassah Medical Organization, Hadassah University Hospital

       

      P.O.B 12000
      Jerusalem 91120 Israel

      Tel: 972-2-6778864

      Fax: 972-2-6778861

  • Lithuania

    • National Cancer Institute

      Santariškių g. 1
      Vilnius LT-08660

      +(85) 219 0924

      https://www.uicc.org/membership/national-cancer-institute-lithuania

  • Mexico

    • Zogen

       

      C. Coras 3515, local 8

      Colonia Monraz

      C.P. 44670, Zapopan, Jalisco

      México

      +52 33 1524 2286

      https://zogen.mx/

  • Portugal

    • Instituto Portuges de Oncologia
      do Porto Francisco Gentil, E.P.E.
      (IPO Porto)

       

      Rua Dr António Bernardino de Almeida, 865
      Porto 4200-072

      +351 225 084 000

      www.ipoporto.pt

       

    • IPATIMUP Diagnósticos

       

      Rua Julio Amaral Carvalho 45
      Porto
      4200-135

      +351-225 570 732

      www.ipatimup.pt

       

  • Roumania

    • Resident Laboratory ltd
      Strada Gheorghe Doja 165, Oradea 410169

  • Spain

    • Anatomia Patológica,
      Hospital Germans Trias I Pujol

       

      Carretera de Canyet s/n
      Badalona 08916

      +34 93 497 88 53

      www.hospitalgermanstrias.cat

       

    • Centro de Diagnóstico Biomédico,

      Hospital Clínic

       

      C/ Villarroel 170

      Barcelona 08036

      +34 93 227 54 00 ext 5472

      www.clinicbarcelona.org

       

    • Fundación Jiménez Díaz

       

      Avda., Reyes Católicos, n 2
      Madrid CP 28040

      +34 91 550 48 00

      www.fjd.es

       

    • Hospital General Universitario
      Gregorio Marañón

       

      C. Dr. Esquerdo 46
      Madrid 28007

      +34 91 529 07 05

      www.comunidad.madrid

       

    • Hospital Universitario
      12 de Octubre

       

      Avda de Córdoba, s/n
      Madrid 28041

      +34 91 390 82 75

      www.comunidad.madrid

       

    • Hospital Universitario de Salamanca

       

      Paseo de la Trancisión s/n
      Salamanca 37007

      +34 92 329 11 00 Ext.: 55847 (Pathology)
      +34 923 136 783

      www.saludcastillayleon.es/CASalamanca/es

       

    • IMIBIC – Hospital Universitario
      Reina Sofia

       

      Av. Menendez Pidal, s/n
      Córdoba 14004

      +34 95 7213 759

      www.imibic.org

       

    • Oncogenomics SL

       

      C/Arturo Soria 17
      Madrid 28027

      +34 607 95 68 20

      www.oncogenomics.es

       

    • Pangaea Oncology S.A.

       

      Sabino Arana 5
      Barcelona 08028

      +34 93 546 01 40

      www.panoncology.com

       

    • SYNLAB Diagnósticos Globales

       

      Carrer Verge de Guadalupe 18
      Barcelona 08950

      +34 933 63 60 00

      www.synlab.es

       

    • Laboratoria de Biología

      Molecular del Cancer. Centro de

      Investigaciones Médico-Sanitarias

       

      C/ Marqués de Beccaria, 3

      Málaga 29010

      +34 952 13 75 61/62

      www.cimes.es

  • Sweden

    • Unilabs Pathology Huvudsta

       

      Anderstorpsvägen 16,
      second floor,
      Solna, Stockholm 17154

      46732598273

      www.unilabs.com

  • Turkey

    • Acıbadem University

       

      Kayışdağı Cad.
      No:32 Ataşehir
      Istanbul

      +0216 661 46 47
      +0533 693 91 01

HEALTH INSURANCE COVERAGE

The Prosigna test is covered by an increasing number of public healthcare systems across the world. In Europe Prosigna is backed by leading Health Technology Assessment (HTA) agencies and/or decision makers such as:

  • England and Wales – National Institute for Health and Care Excellence (NICE)
  • France – Haute Autorité de Santé (HAS)
  • Germany – Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen/Gemeinsamer Bundesausschuss (IQWIG/G-BA)
  • Italy – Ministero della Salute
  • Norway – Beslutningsforum
  • Scotland – Scottish Health Technologies Group (SHTG)
  • Sweden – TLV (Tandvårds- och Läkemedelsformånsverket) ordered by the Medical Products Council (MTP-rådet)
  • Switzerland – Bundesamt für Gesundheit (BAG)

Prosigna is also reimbursed in Denmark, Israel, Lithuania, Spain and other countries.

To find out if the Prosigna test is covered in your country and for more information on your reimbursement status or private insurance options, please get in touch with our customer care team.

  • For Europe, Middle East and Africa, please contact us.
    Contact us
  • For Canada, Latin America and Oceania, please contact us.
    Contact us

NEWS

  • Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test
    READ MORE
  • Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
    READ MORE

VIDEOS

  •
    Helping patients understand their gene expression profiling (GEP) risk of recurrence scores

    What are the ways to help breast cancer patients understand their risk of recurrence scores? In his webinar, Professor Dame Lesley Fallowfield discusses the successful TARGET educational programme in the UK and the IMPARTER study, which examines if provision of a specific patient information film improves knowledge about gene expression profiling (GEP) and enhances satisfaction with patient-clinician discussions.

    Speaker: Professor Dame Lesley Fallowfield

    • Discuss the TARGET educational programme in the UK
    • Learn about the IMPARTER study
    • Discover patient information films

    *This session is intended for physicians practicing outside of the U.S., however, U.S.-based physician’s are welcome to attend.​

  •
    What are the advantages of using a second-generation genomic test?
    What are the advantages of using a second-generation genomic test? What is the utility of intrinsic subtyping in the clinic? The past, present and future. Interactive webinar designed for doctors treating breast cancer interested in advancing personalized treatment through molecular gene expression testing.

    Speaker: P. Kelly Marcom, MD | Medical Director-Breast Cancer, Veracyte Understand the potential of Prosignaⓐ

     

    • Discuss the advantages of using a second-generation genomic test
    • Learn about the utility of intrinsic subtyping in the clinic
    • Live discussion and debates looking at the past, present and future.
  •
    Prosigna At a Glance: Clinical implications of the breast cancer intrinsic subtypes
    This program is focused on highlighting the added value of Prosigna@ Breast Cancer Assay with the collaboration of key opinion leaders. To learn more, we invite you to watch this presentation with Dr. Ciruelos talking about the utility of the PAM50 intrinsic subtypes.
  • Differences between 1st and 2nd generation gene expression profile tests: which perform best and why?
    How do you do a direct comparison of prognostic performance across multiple molecular gene expression assays? To learn more, we invite you to watch this presentation of Dr. Ivana Sestak at SFSPM 2021 on molecular gene expression assays used to guide treatment of HR+ early-stage cancer. (English)
  • Clinical evidence of molecular subtypes as prognostic and predictive value in HR+/Her2- breast cancers with or without lymph nodes
    SFSPM 2021, Marie-Ange Mouret-Reynier talks about molecular gene expression assays integrated into the patient pathway: new clinical data and feedback in France. (French)
  • Real world multicenter study on the use of Prosigna® in France: therapeutic and economic impacts
    Roman Rouzier presents at SFSPM 2021 the outcome of a real-world multicenter study on the use of Prosigna Breast Cancer Assay in France and analyzes the therapeutic and economic impacts (French).

    This French study highlighted:

     

    • The utility of Prosigna in real-world setting
    • Prosigna beneficial budgetary impact in France
    • Prosigna provides more information than other gene expression profile tests
  •
    Association of Breast Surgery (ABS) - Veracyte Sponsored Event
    We invite you to watch this panel discussion and case study presentation on the Prosigna® Breast Cancer Prognostic Gene Signature Assay with:
    • Professor Mark Beresford – Clinical Oncologist
    • Dr Marina Parton – Medical Oncologist
    • Dr Judy King – Medical Oncologist
    • Professor Abeer Shaaban – Breast Pathologist
    • Mr James Harvey – Breast Surgeon
  •
    Veracyte Symposium – Genomic testing in breast cancer – more precision medicine? 
    This Veracyte symposium was recorded at the SweBCG SOTA meeting, October 2021, Malmö, Sweden. 
    • Swedish guidelines for testing in breast cancer and experiences from Stockholm – Prof. Johan Hartman, Karolinska Institutet
    • Risk of recurrence and clinical utility of luminal subtypes – Prof Matthew J. Ellis, Baylor College of Medicine
    • Next level personalized treatment decisions – the OPTIMA trial – Prof Robert Stein, University College London
  •
    The history and evolution of PAM50 & Prosignaⓐ
    The history and evolution of PAM50 & Prosignaⓐ from the laboratory to the clinic: how accurate biological classification can be used to best treat your patients. Live discussion and debates looking at the history and origins of PAM50 and Prosigna and the adoption process in a reference center in Heidelberg, Germany.

    Speakers: Charles M. Perou, PhD, Prof. Torsten O. Nielsen and Dr. phil. Martina Kirchner

     

    • Understand the history and origin of PAM50 & Prosigna
    • Discuss their evolution from the laboratory to the clinic
    • Learn how accurate biological classification can be used to best treat your patients
  •
    How can intrinsic molecular subtypes guide therapeutic decisions for breast cancer patients?
    Live discussion looking how can intrinsic molecular subtypes guide therapeutic decisions for breast cancer patients. The presentations is supported by reports based discussions.

     

    Speakers:

     

    • Pr Frédérique Penault-Llorca
    • Pr Gilles Freyer
    • Dr Olivier Tredan